Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07333131

Identification of Iatrogenic Drug Events Upon Admission to the Adult Emergency Departments

Pharmacists working within a multidisciplinary team have a role to play in detecting the potential iatrogenic origin of a hospital admission, in order to implement measures to improve medication use appropriately and limit readmissions for medication-related iatrogenesis. The iatrogenic detection process depends on the individual involved, their experience, and any tools consulted. Indeed, detection aids have their place in this process and aim for better identification. For example, a questionnaire called AT HARM 10 was developed by a team of experienced pharmacists to identify hospitalizations related to medication-related iatrogenesis. The use of this tool has been validated for pharmacists as well as for pharmacy students: interns and fifth-year medical students.

Identifying iatrogenic drug events among patients presenting to the emergency department using the AT HARM 10 grid in order to intervene and adapt therapeutic management. This clinical pharmacy activity complements what is already included in routine care (medication review, pharmaceutical analysis, and pharmaceutical intervention to adapt treatment).

Recruiting

Interested in participating?

Request Info

Key information

Age range

66 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service de Pharmacie - Stérilisation - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Elsa FORET, PharmD

SUB_INVESTIGATOR

Etienne QUOIRIN, MD

SUB_INVESTIGATOR

Julia WALTHER, PharmD

CONTACT

[email protected]

33 3 88 12 78 18

Julia WALTHER, PharmD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patient (> 65 years old)
  • Treated in the emergency department of Hautepierre Hospital
  • Presenting a prioritization score > 7 according to the Von Korff score
  • Subject (and their legal representative, if applicable) not objecting to the reuse of their data for scientific research purposes.

Exclusion criteria

  • Presence of a written objection in the patient's medical file (and/or that of their legal representative, if applicable) to the reuse of their data for scientific research purposes

Treatment and study plan

Primary outcomes

  1. Number of patients for whom an iatrogenic event was identified

    Time frame: Up to 9 months

Study contacts

Contact information is provided by the study sponsor or research team.

Julia WALTHER, PharmD

CONTACT

[email protected]

33 3 88 12 78 18

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: IATRO-URG

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 12, 2026
Registry last updated
Jan 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.